Transcriptomic Portraits and Molecular Pathway Activation Features of Adult Spinal Intramedullary Astrocytomas

In this study, we report 31 spinal intramedullary astrocytoma (SIA) RNA sequencing (RNA-seq) profiles for 25 adult patients with documented clinical annotations. To our knowledge, this is the first clinically annotated RNA-seq dataset of spinal astrocytomas derived from the intradural intramedullary...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 837570
Main Authors Konovalov, Nikolay, Timonin, Stanislav, Asyutin, Dmitry, Raevskiy, Mikhail, Sorokin, Maxim, Buzdin, Anton, Kaprovoy, Stanislav
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 21.03.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:In this study, we report 31 spinal intramedullary astrocytoma (SIA) RNA sequencing (RNA-seq) profiles for 25 adult patients with documented clinical annotations. To our knowledge, this is the first clinically annotated RNA-seq dataset of spinal astrocytomas derived from the intradural intramedullary compartment. We compared these tumor profiles with the previous healthy central nervous system (CNS) RNA-seq data for spinal cord and brain and identified SIA-specific gene sets and molecular pathways. Our findings suggest a trend for SIA-upregulated pathways governing interactions with the immune cells and downregulated pathways for the neuronal functioning in the context of normal CNS activity. In two patient tumor biosamples, we identified diagnostic fusion oncogenes, and we also found 16 new SIA-associated fusion transcripts. In addition, we bioinformatically simulated activities of targeted cancer drugs in SIA samples and predicted that several tyrosine kinase inhibitory drugs and thalidomide analogs could be potentially effective as second-line treatment agents to aid in the prevention of SIA recurrence and progression.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Giorgio Carrabba, University of Milano-Bicocca, Italy; Mirza Pojskic, University Hospital of Giessen and Marburg, Germany; Nir Shimony, Geisinger Health System, United States
This article was submitted to Cancer Genetics, a section of the journal Frontiers in Oncology
Edited by: Tzu Pin Lu, National Taiwan University, Taiwan
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.837570